A comprehensive DNA methylation profile of epithelial-to-mesenchymal transition

Cancer Research

Volumn 74, Issue 19, 2014, Pages 5608-5619

  Carmona, F Javier ^a   Davalos, Veronica ^a   Vidal, Enrique ^a   Gomez, Antonio ^a   Heyn, Holger ^a   Hashimoto, Yutaka ^a   Vizoso, Miguel ^a   Martinez Cardus, Anna ^a   Sayols, Sergi ^a   Ferreira, Humberto J ^a   Sánchez Mut, Jose V ^a   Morán, Sebastián ^a   Margelí, Mireia ^b   Castella, Eva ^c   Berdasco, Maria ^a   Stefansson, Olafur A ^a   Eyfjord, Jorunn E ^d   Gonzalez Suarez, Eva ^a   Dopazo, Joaquín ^e,f   Orozco, Modesto ^g,h,i   Gut, Ivo G ^j   Esteller, Manel ^a,i,k   more..

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b Centre of Epidemiological Studies on STI HIV and AIDS in Catalonia (CEEISCAT)   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d UNIVERSITY OF ICELAND   (Iceland)

^e CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^f CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^g INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^h BARCELONA SUPERCOMPUTING CENTER   (Spain)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j Centre Nacional d'Analisi Genomica CNAG   (Spain)

^k INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BREAST TUMOR; DNA METHYLATION; DOG; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENETICS; HUMAN; MDCK CELL LINE; PATHOLOGY;

ANIMALS; BREAST NEOPLASMS; DNA METHYLATION; DOGS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MADIN DARBY CANINE KIDNEY CELLS;

EID: 84907562669     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3659     Document Type: Article

References (52)

1. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116:544-73.
2. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
3. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265-73.
4. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
5. Tiwari N, Gheldof A, Tatari M, Christofori G. EMT as the ultimate survival mechanism of cancer cells. Semin. Cancer Biol 2012;22:194-207.
6. Brabletz T. To differentiate or not-routes towards metastasis. Nat. Rev. Cancer 2012;12:425-436.
7. McDonald OG, Wu H, Timp W, Doi A, Feinberg AP. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat Struct Mol Biol 2011;18:867-874.
8. Vrba L, Jensen TJ, Garbe JC, Heimark RL, Cress AE, Dickinson S, et al. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS ONE 2010;5:e8697.
9. Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt L, Ramanathan R, Hansen TB, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011;128:1327-34.
10. Tellez CS, Juri DE, Do K, Bernauer AM, Thomas CL, Damiani LA, et al. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogeninduced transformation of human lung epithelial cells. Cancer Res 2011;71:3087-97.
11. Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F, et al. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 2012;31:2062-74.
12. Gaush CR, Hard WL, Smith TF. Characterization of an established line of canine kidney cells MDCK. Proc Soc Exp Biol Med 1966;122:931-5.
13. Moreno-Bueno G, Peinado H, Molina P, Olmeda D, Cubillo E, Santos V, et al. The morphological and molecular features of the epithelial-tomesenchymal transition. Nat. Protoc 2009;4:1591-613.
14. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005;24:5764-74.
15. Stefansson OA, Jonasson JG, Olafsdottir K, Hilmarsdottir H, Olafsdottir G, Esteller M, et al. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. Epigenetics 2011;6:638-49.
16. Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 2011;27:1571-2.
17. Haider S, Ballester B, Smedley D, Zhang J, Rice P, Kasprzyk A. BioMart Central Portal-unified access to biological data. Nucleic Acids Res 2009;37:W23-7.
18. Fujita PA, Rhead B, Zweig AS, Hinrichs AS, Karolchik D, Cline MS, et al. The UCSC genome browser database: update. Nucleic Acids Res 2011;39:D876-82.
19. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics 2009;25:2078-9.
20. Li H. Tabix: fast retrieval of sequence features from generic TAB-delimited files. Bioinformatics 2010;27:718-9.
21. Hansen KD, Langmead B, Irizarry RA. BSmooth: from whole genome bisulfite sequencing reads to differentially methylated regions. Genome Biol 2012;13:R83.
22. Berdasco M, Fraga MF, Esteller M. Quantification of global DNA methylation by capillary electrophoresis and mass spectrometry. Methods Mol Biol 2009;507:23-34.
23. Carmona FJ, Azuara D, Berenguer-Llergo A, Fernandez AF, Biondo S, deOca J, etal. DNA methylation biomarkers for noninvasive diagnosis of colorectal cancer. Cancer Prev Res Phila 2013;6:656-65.
24. Fernandez AF, Rosales C, Lopez-Nieva P, Grana O, Ballestar E, Ropero S, et al. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res 2009;19:438-51.
25. Sandoval J, Heyn H, Moran S, Serra-Musach J, Pujana MA, Bibikova M, et al. Validation of a DNA methylation microarray for 450, 000 CpG sites in the human genome. Epigenetics 2011;6:692-702.
26. Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, et al. Highdensity DNA methylation array with single CpG site resolution. Genomics 2011;98:288-95.
27. Xu H, Handoko L, Wei X, Ye C, Sheng J, Wei CL, et al. A signal-noise model for significance analysis of ChIP-seq with negative control. Bioinformatics 2010;26:1199-204.
28. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 2010;26:841-2.
29. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Circos: an information aesthetic for comparative genomics. Genome Res 2009;19:1639-45.
30. Bernstein BE, Stamatoyannopoulos JA, Costello JF, Ren B, Milosavljevic A, Meissner A, et al. The NIH Roadmap Epigenomics Mapping Consortium. Nat Biotechnol 2010;28:1045-8.
31. Heyn H, Li N, Ferreira HJ, Moran S, Pisano DG, Gomez A, et al. Distinct DNA methylomes of newborns and centenarians. Proc Natl Acad Sci USA 2012;109:10522-7.
32. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011;11:726-734.
33. Heyn H, EstellerM. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 2012;13:679-92.
34. Ball MP, Li JB, Gao Y, Lee JH, LeProust EM, Park IH, et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 2009;27:361-8.
35. Zemach A, McDaniel IE, Silva P, Zilberman D. Genome-wide evolutionary analysis of eukaryotic DNA methylation. Science 2010;328:916-9.
36. Kulis M, Heath S, Bibikova M, Queiros AC, Navarro A, Clot G, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 2012;44:1236-42.
37. Forrest MP, Waite AJ, Martin-Rendon E, Blake DJ. Knockdown of human TCF4 affects multiple signaling pathways involved in cel survival, epithelial to mesenchymal transition and neuronal differentiation. PLoS ONE 2013;8:e73169.
38. Cieply B, Riley PIV, Pifer PM, Widmeyer J, Addison JB, Ivanov AV, et al. Suppression of the epithelial-mesenchymal transition by Grainyheadlike-2. Cancer Res 2012;72:2440-53.
39. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celia-Terrassa T, et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 2011;17:1101-8.
40. Min SW, Chang WP, Sudhof TC. E-Syts, a family of membranous Ca2+-sensor proteins with multiple C2 domains. Proc Natl Acad Sci USA 2007;104:3823-8.
41. Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA. Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res 2010;70:5147-54.
42. Quinn MC, Wojnarowicz PM, Pickett A, Provencher DM, Mes-Masson AM, Davis EC, et al. FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome. Int J Oncol 2013;42:912-20.
43. Vantyghem SA, Allan AL, Postenka CO, Al-Katib W, Keeney M, Tuck AB, et al. A new model for lymphatic metastasis: development of a variant of the MDA-MB-468 human breast cancer cell line that aggressively metastasizes to lymph nodes. Clin Exp Metastasis 2005;22:351-61.
44. Andrews J1, Kennette W, Pilon J, Hodgson A, Tuck AB, Chambers AF, et al. Multi-platform whole-genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number. PLoS ONE 2010;5:e8665.
45. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008 68:989-97.
46. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-71.
47. Maschler S, Wirl G, Spring H, Bredow DV, Sordat I, Beug H, et al. Tumor cell invasiveness correlates with changes in integrin expression and localization. Oncogene 2005;24:2032-41.
48. Gong J, Wang D, Sun L, Zborowska E, Willson JK, Brattain MG. Role of alpha 5 beta 1 integrin in determining malignant properties of colon carcinoma cells. Cell Growth Differ 1997;8:83-90.
49. Qian F, Zhang ZC, Wu XF, Li YP, Xu Q. Interaction between integrin alpha 5 and fibronectin is required for metastasis of B16F10 melanoma cells. Biochem Biophys Res Commun 2005;333:1269-75.
50. Tani N, Higashiyama S, Kawaguchi N, Madarame J, Ota I, Ito Y, et al. Expression level of integrin alpha 5 on tumour cells affects the rate of metastasis to the kidney. Br J Cancer 2003;88:327-33.
51. Ishikawa Y, Vranka J, Wirz J, Nagata K, Bachinger HP. The rough endoplasmic reticulum-resident FK506-binding protein FKBP65 is a molecular chaperone that interacts with collagens. J Biol Chem 2008;283:31584-90.
52. Patterson CE, Abrams WR, Wolter NE, Rosenbloom J, Davis EC. Developmental regulation and coordinate reexpression of FKBP65 with extracellular matrix proteins after lung injury suggest a specialized function for this endoplasmic reticulum immunophilin. Cell Stress Chaperones 2005;10:285-95.